Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04908228
Title Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naive Patients With CLL
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Paolo Ghia
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Ibrutinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries ITA

Additional content available in CKB BOOST